Identification of responders to rivastigmine: A prospective cohort study

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 1, 2007, Pages 60-66

  Lemstra, Afina W ^a   Kuiper, Roy B ^a   Schmand, Ben ^a   Van Gool, Willem A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cholinesterase inhibitors; Dementia; Neuropsychology, cognitive

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; ANXIETY; APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CLUSTER ANALYSIS; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DELUSION; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; LOCOMOTION; MALE; MULTIINFARCT DEMENTIA; NAUSEA; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMOTOR DISORDER; RANK SUM TEST; REACTION TIME; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SWEDEN;

EID: 37349014581     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111549     Document Type: Article

References (45)

1. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593.
2. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
3. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
4. http://www.nice.org.uk/CG035 (accessed 2006).
5. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL: The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
6. Farlow MR, Small GW, Quarg P, Krause A: Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord 2005;20:192-197.
7. Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A: The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol 2003;26:239-251.
8. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT: Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry 2003;18:879-886.
9. Van der Putt R, Dineen C, Janes D, Series H, McShane R: Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice. Int J Geriatr Psychiatry 2006;21:755-760.
10. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.
11. Herrmann N, Rabheru K, Wang J, Binder C: Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005;13:527-534.
12. McKeith IG, Wesnes KA, Perry E, Ferrara R: Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004;18:94-100.
13. Connelly PJ, Prentice NP, Fowler KG: Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76:320-324.
14. Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H: Cognitive predictors of donepezil therapy response in Alzheimer disease. Dement Geriatr Cogn Disord 2007;24:28-35.
15. Adler G, Brassen S, Chwalek K, Dieter B, Teufel M: Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 2004;75:292-294.
16. Csernansky JG, Wang L, Miller JP, Galvin JE, Morris JC: Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch Neurol 2005;62:1718-1722.
17. DiLazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C, Ghirlanda S, Ranieri F, Gainotti G, Tonali P: Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J Neurol Neurosurg Psychiatry 2005;76:1064-1069.
18. Hanyu H, Tanaka Y, Sakurai H, Takasaki M, Abe K: Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease. Neurosci Lett 2002;319:33-36.
19. Tanaka M, Namiki C, Thuy DH, Yoshida H, Kawasaki K, Hashikawa K, Fukuyama H, Kita T: Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J Neurol Sci 2004;225:135-141.
20. Lemstra AW, Eikelenboom P, van Gool WA: The cholinergic deficiency syndrome and its therapeutic implications. Gerontology 2003;49:55-60.
21. Forrer GR, Miller JJ: Atropine coma: a somatic therapy in psychiatry. Am J Psychiatry 1958;115:455-458.
22. Itil T, Fink M: Anticholinergic drug-induced delirium: experimental modification, quantitative EEG and behavioral correlations. J Nerv Ment Dis 1966;143:492-507.
23. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
25. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
26. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
28. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, DSM-IV, ed 4. Washington, American Psychiatric Association, 1996.
29. Teunisse S, Derix MM: The interview for deterioration in daily living activities in dementia: agreement between primary and secondary caregivers. Int Psychogeriatr 1997;9(suppl 1):155-162.
30. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-2314.
31. Fahn S, Elton R; Unified Parkinson's Disease Rating Development Committee: Unified Parkinson's Disease Rating Scale; in Fahn S (ed): Recent Developments in Parkinson's Disease. New York, Macmillan, 1987, pp 153-163.
32. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-256.
33. Stroop JR: Studies of interference in serial verbal reactions. J Exp Psychol 1935;28:643-662.
34. Aldenkamp AP, Vermeulen J, Alpherts WCJ, Overweg J, van Parijs JAP, Verhoeff NPLG: Validity of computerized testing: patient dysfunction and complaints versus measured changes; in Dodson WE, Kinsbourne M (eds): Assessment of Cognitive Function. New York, Demos, 1992, pp 51-68.
35. Lindeboom J, Koene T, Matto D: The diagnostic value of tests for mental control. Tijdschr Gerontol Geriatr 1993;24:105-109.
36. Gronwall DM: Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977;44:367-373.
37. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C: Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73:126-133.
38. Tune LE, Egeli S: Acetylcholine and delirium. Dement Geriatr Cogn Disord 1999;10:342-344.
39. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404.
40. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219.
41. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
42. Birks J, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000;CD001191.
43. Burn DJ, McKeith IG: Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003;18(suppl 6):S72-S79.
44. Maidment I, Fox C, Boustani M: Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006;CD004747.
45. Wild R, Pettit T, Burns A: Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003;CD003672.